Irinotecan is a topoisomerase I inhibitor, functioning as a prodrug converted to 7-ethyl-10-hydroxycamptothecin. It exhibits broad antitumor activity, especially against metastatic colorectal cancer, small cell lung cancer, and solid tumors, and enhances radiation therapy effectiveness. Reagent grade, for research purpose.
Usually ships within 24 hours.